Conference Coverage

Chlamydia infections associated with more than a doubling of ovarian cancer risk


 

FROM THE AACR ANNUAL MEETING

Pelvic inflammatory disease caused by chlamydia appears to significantly increase the risk of ovarian cancer, according to research to be presented at the annual meeting of the American Association for Cancer Research.

The finding, replicated in two large databases, suggests that promptly treating the infection might reduce the lifetime risk of developing ovarian cancer, Britton Trabert, PhD, said during a press briefing held in advance of the meeting.

Dr. Britton Trabert, National Cancer Institute, Bethesda, Md.

Dr. Britton Trabert

“Although these findings need to be replicated, they suggest potential ovarian cancer risk reduction through targeted treatment of chlamydia infections,” said Dr. Trabert, the Earl Stadtman Investigator at the National Cancer Institute.

The study portends both promise and challenge, according to Elaine R. Mardis, PhD, who comoderated the session.

Pages

Recommended Reading

As government-funded cancer research sags, scientists fear U.S. is ‘losing its edge’
MDedge Internal Medicine
Is pain or dependency driving elevated opioid use among long-term cancer survivors?
MDedge Internal Medicine
FDA approves biosimilar to bevacizumab
MDedge Internal Medicine
Missed opportunities abound to give HPV vaccine to adolescent girls
MDedge Internal Medicine
Adolescents with chronic health conditions often undervaccinated
MDedge Internal Medicine
FDA: Laparoscopic power morcellators can spread malignant cells when used in women with occult uterine cancers*
MDedge Internal Medicine
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Internal Medicine
USPSTF: Routine screens for ovarian cancer not recommended
MDedge Internal Medicine
Telling her she has cancer: A patient-centered approach to breaking bad news
MDedge Internal Medicine
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Internal Medicine